Fulcrum Therapeutics, Inc.

FULC

Find Out if You Qualify for a Financial Reward by filling out the form below.

Fulcrum Therapeutics, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Fulcrum announced on September 12, 2024, that “its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance.”

Following this news, Fulcrum stock dropped 60% in morning trading on the same day.

Active Cases

Ticker Symbol Company Name Join Deadline Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join
SUI Sun Communities, Inc. February 10, 2025 Join
SAVA Cassava Sciences, Inc. February 10, 2025 Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join